SILO Silo Pharma Inc.

Subscribe to $SILO

Silo Pharma Inc.

Subscribe to $SILO

$SILO

Apparel

Consumer Discretionary

IPO Year:

Exchange: NASDAQ

Recent Analyst Ratings for Silo Pharma Inc.

Date	Price Target	Rating	Analyst

See more ratings

Silo Pharma Inc. Press Releases

Fastest customizable press release news feed in the world

Silo Pharma Enters into Letter of Intent to Form Joint Venture with Hoth Therapeutics to Develop Obesity Treatment Targeting $16 Billion Global Market
Technology Co-Developed by the U.S. Department of Veterans Affairs and Emory University NEW YORK, June 25, 2025 (GLOBE NEWSWIRE) -- Silo Pharma, Inc. (NASDAQ:SILO) ("Silo" or the "Company"), a developmental stage biopharmaceutical company focused on novel therapeutics and drug delivery systems, today announced that it has entered into a non-binding letter of intent to form a strategic 50:50 joint venture with Hoth Therapeutics, Inc. (NASDAQ:HOTH) to develop and commercialize a potential treatment for obesity and metabolic disease based on technology Hoth has exclusively licensed from the U.S. Department of Veterans Affairs (VA) that was co-developed by the VA and Emory University. The n
6/25/25 8:38:00 AM ET
$HOTH
$SILO
Biotechnology: Pharmaceutical Preparations
Health Care
Apparel
Consumer Discretionary
Hoth Therapeutics (HOTH) and Silo Pharma (NASDAQ: SILO) today announced the formation of a 50/50 joint venture to develop a first-in-class GDNF-based therapy licensed from the U.S. Department of Veterans Affairs. The therapy targets obesity and fatty liver disease.
*Hoth Therapeutics and Silo Pharma Launch Joint Venture to Commercialize VA-Invented Obesity Drug Targeting $100B+ Global Market Exclusive License from U.S. Department of Veterans Affairs to Advance GDNF-Based Therapy for Obesity and Fatty Liver Disease NEW YORK, June 25, 2025 /PRNewswire/ -- Hoth Therapeutics, Inc. (NASDAQ:HOTH) and Silo Pharma, Inc. (NASDAQ:SILO) today announced the formation of a strategic joint venture to develop and commercialize a first-in-class treatment for obesity and metabolic disease based on technology exclusively licensed from the U.S. Department of Veterans Affairs (VA).
6/25/25 8:27:00 AM ET
$HOTH
$SILO
Biotechnology: Pharmaceutical Preparations
Health Care
Apparel
Consumer Discretionary
Silo Pharma Secures Biomarker Patent for Novel PTSD Therapeutic SPC-15 as Clinical Trial Nears
SARASOTA, FL, June 11, 2025 (GLOBE NEWSWIRE) -- Silo Pharma, Inc. (NASDAQ:SILO) ("Silo" or the "Company"), a developmental stage biopharmaceutical company focused on novel therapeutics and drug delivery systems, today announced that the U.S. Patent and Trademark Office (USPTO) had issued a Notice of Allowance for U.S. Patent Application No. 17/954,858 (titled "Biomarkers for Efficacy of Prophylactic Treatments Against Stress-Induced Affective Disorders") that Silo licenses from Columbia University. The to-be-issued patent will further strengthen Silo's IP protection for its lead asset, SPC-15, an intranasal treatment targeting post-traumatic stress disorder (PTSD). The patent is expected
6/11/25 9:00:00 AM ET
$SILO
Apparel
Consumer Discretionary
Silo Pharma Board of Directors Approves Purchase of Bitcoin as Treasury Reserve Asset
SARASOTA, FL, June 05, 2025 (GLOBE NEWSWIRE) -- Silo Pharma, Inc. (NASDAQ:SILO) ("Silo" or the "Company"), a developmental stage biopharmaceutical company focused on novel therapeutics and drug delivery systems, today announced that its Board of Directors has approved the purchase of up to $1 million in Bitcoin as a treasury reserve asset. "The addition of Bitcoin to our treasury holdings is a strategic decision aimed at diversifying our assets to include a digital store of value with what we believe has significant upside potential," said Eric Weisblum, CEO of Silo. "Our purchase of Bitcoin is intended to provide a safeguard against inflation and is expected to position Silo to preserv
6/5/25 9:15:00 AM ET
$SILO
Apparel
Consumer Discretionary
Silo Pharma Partners with Resyca for IND-Supporting Intranasal Drug-Device Study of PTSD Drug SPC-15
SARASOTA, FL, May 21, 2025 (GLOBE NEWSWIRE) -- Silo Pharma, Inc. (NASDAQ:SILO) ("Silo" or the "Company"), a developmental stage biopharmaceutical company focused on novel therapeutics and drug delivery systems, today announced that it has entered into a service agreement with medical technology provider Resyca BV for a drug-device study of the formulation-specific microchip-based nasal spray system used in its lead asset SPC-15, an intranasal prophylactic treatment for post-traumatic stress disorder (PTSD). "This study is expected to provide the final necessary device data and documentation for SPC-15's IND, which we plan to submit to the FDA this year," said Eric Weisblum, CEO of Silo. "
5/21/25 8:55:00 AM ET
$SILO
Apparel
Consumer Discretionary
Silo Pharma Announces Closing of $2 Million Public Offering
SARASOTA, FL, May 16, 2025 (GLOBE NEWSWIRE) -- Silo Pharma, Inc. (NASDAQ:SILO) ("Silo" or the "Company"), a developmental stage biopharmaceutical company focused on novel therapeutics and drug delivery systems, closed on the previously announced public offering of 3,333,338 shares of common stock (or pre-funded warrants in lieu thereof), together with series A-1 warrants ("Series A-1 Warrants") to purchase up to 3,333,338 shares of common stock and series A-2 warrants ("Series A-2 Warrants") to purchase up to 3,333,338 shares of common stock at a combined public offering price of $0.60 per share (or pre-funded warrant in lieu thereof) and associated Series A-1 Warrant and Series A-2 Warran
5/16/25 4:15:00 PM ET
$SILO
Apparel
Consumer Discretionary
Silo Pharma Announces Pricing of $2 Million Public Offering
SARASOTA, FL, May 15, 2025 (GLOBE NEWSWIRE) -- Silo Pharma, Inc. (NASDAQ:SILO) ("Silo" or the "Company"), a developmental stage biopharmaceutical company focused on novel therapeutics and drug delivery systems, today announced the pricing of a public offering of 3,333,338 shares of common stock (or pre-funded warrants in lieu thereof), together with series A-1 warrants ("Series A-1 Warrants") to purchase up to 3,333,338 shares of common stock and series A-2 warrants ("Series A-2 Warrants") to purchase up to 3,333,338 shares of common stock at a combined public offering price of $0.60 per share (or pre-funded warrant in lieu thereof) and associated Series A-1 Warrant and Series A-2 Warrant.
5/15/25 9:15:00 AM ET
$SILO
Apparel
Consumer Discretionary
Silo Pharma Selects Veloxity Labs for Bioanalytical IND-Enabling Study for our Novel Intranasal PTSD Therapy, SPC-15
SARASOTA, FL, May 14, 2025 (GLOBE NEWSWIRE) -- Silo Pharma, Inc. (NASDAQ:SILO) ("Silo" or the "Company"), a developmental stage biopharmaceutical company focused on novel therapeutics and drug delivery systems, today announced that it has engaged Veloxity Labs, LLC for bioanalysis supporting the ongoing investigational new drug (IND)-enabling GLP (Good Laboratory Practice)-compliant toxicology and toxicokinetics study of its lead asset, SPC-15, an intranasal prophylactic treatment for post-traumatic stress disorder (PTSD). "We look forward to working with Veloxity Labs for GLP sample analysis in our current safety study of SPC-15," said Eric Weisblum, CEO of Silo. "We expect Veloxity to p
5/14/25 4:07:00 PM ET
$SILO
Apparel
Consumer Discretionary
Silo Pharma Advances PTSD Drug SPC-15 Toward First-in-Human Trial with Key Safety Study Initiated at Frontage Laboratories
SARASOTA, FL, May 14, 2025 (GLOBE NEWSWIRE) -- Silo Pharma, Inc. (NASDAQ:SILO) ("Silo" or the "Company"), a developmental stage biopharmaceutical company focused on novel therapeutics and drug delivery systems, today announced that it has entered into an agreement with Frontage Laboratories, a global full-service CRO (contract research organization), for a Food and Drug Administration (FDA) requested 7-day safety and toxicology large animal study of its lead asset SPC-15, an intranasal prophylactic treatment for post-traumatic stress disorder (PTSD). "We are conducting a 7-day safety and toxicology study to gather additional data that is expected to supplement and reinforce our SPC-15 inv
5/14/25 8:40:00 AM ET
$SILO
Apparel
Consumer Discretionary
Silo Pharma's SP-26 Ketamine Implant Meets All Endpoints in Fibromyalgia Study
— Successfully demonstrates strong tolerability, sustained drug release and safety SARASOTA, FL, April 30, 2025 (GLOBE NEWSWIRE) -- Silo Pharma, Inc. (NASDAQ:SILO) ("Silo," or the "Company"), a developmental stage biopharmaceutical company focused on novel therapeutics and drug delivery systems, today announced positive results for its preclinical study evaluating SP-26, a novel extended-release ketamine implant which it believes supports SP-26's potential as a safe, well-tolerated, and long-acting treatment for fibromyalgia. All study endpoints were met, including survival, clinical observations, body weight stability, neurological assessments, and histopathological evaluation. "Our t
4/30/25 8:11:00 AM ET
$SILO
Apparel
Consumer Discretionary

Silo Pharma Inc.

Recent Analyst Ratings for Silo Pharma Inc.

Silo Pharma Inc.

Recent Analyst Ratings for Silo Pharma Inc.

Silo Pharma Inc. SEC Filings

Silo Pharma Inc. filed SEC Form 8-K: Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing

Silo Pharma Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Other Events, Financial Statements and Exhibits

SEC Form 424B4 filed by Silo Pharma Inc.

SEC Form EFFECT filed by Silo Pharma Inc.

Amendment: SEC Form S-1/A filed by Silo Pharma Inc.

SEC Form 10-Q filed by Silo Pharma Inc.

Amendment: SEC Form S-1/A filed by Silo Pharma Inc.

SEC Form S-1 filed by Silo Pharma Inc.

SEC Form 424B3 filed by Silo Pharma Inc.

SEC Form EFFECT filed by Silo Pharma Inc.

Silo Pharma Inc. Insider Trading

Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

Chief Executive Officer Weisblum Eric bought $4,329 worth of shares (10,000 units at $0.43), increasing direct ownership by 5% to 197,932 units (SEC Form 4)

SEC Form 4 filed by Director Linsley Wayne

SEC Form 4 filed by Director Munoz Kevin

SEC Form 4 filed by Chief Financial Officer Ryweck Daniel E.

SEC Form 4 filed by Chief Executive Officer Weisblum Eric

SEC Form 4 filed by Director Pavell Jeff

CEO and President Weisblum Eric bought $2,097 worth of shares (2,500 units at $0.84), increasing direct ownership by 1% to 187,932 units (SEC Form 4)

CEO and President Weisblum Eric bought $4,625 worth of shares (5,000 units at $0.93), increasing direct ownership by 3% to 185,432 units (SEC Form 4)

CEO and President Weisblum Eric bought $5,533 worth of shares (5,000 units at $1.11), increasing direct ownership by 3% to 180,432 units (SEC Form 4)

Weisblum Eric bought $1,988 worth of shares (1,000 units at $1.99), increasing direct ownership by 0.57% to 175,432 units (SEC Form 4)

Silo Pharma Inc. Insider Purchases

Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

Chief Executive Officer Weisblum Eric bought $4,329 worth of shares (10,000 units at $0.43), increasing direct ownership by 5% to 197,932 units (SEC Form 4)

CEO and President Weisblum Eric bought $2,097 worth of shares (2,500 units at $0.84), increasing direct ownership by 1% to 187,932 units (SEC Form 4)

CEO and President Weisblum Eric bought $4,625 worth of shares (5,000 units at $0.93), increasing direct ownership by 3% to 185,432 units (SEC Form 4)

CEO and President Weisblum Eric bought $5,533 worth of shares (5,000 units at $1.11), increasing direct ownership by 3% to 180,432 units (SEC Form 4)

Weisblum Eric bought $1,988 worth of shares (1,000 units at $1.99), increasing direct ownership by 0.57% to 175,432 units (SEC Form 4)

Weisblum Eric bought $8,713 worth of shares (4,508 units at $1.93), increasing direct ownership by 3% to 174,432 units (SEC Form 4)

Weisblum Eric bought $1,137 worth of shares (700 units at $1.62), increasing direct ownership by 0.41% to 169,924 units (SEC Form 4)

Weisblum Eric bought $1,668 worth of shares (1,100 units at $1.52), increasing direct ownership by 0.65% to 169,224 units (SEC Form 4)

Weisblum Eric bought $1,376 worth of shares (1,000 units at $1.38), increasing direct ownership by 0.60% to 168,124 units (SEC Form 4)

Weisblum Eric bought $3,100 worth of shares (2,000 units at $1.55), increasing direct ownership by 1% to 167,124 units (SEC Form 4)

Silo Pharma Inc. Large Ownership Changes

This live feed shows all institutional transactions in real time.

SEC Form SC 13G filed by Silo Pharma Inc.

SEC Form SC 13G filed by Silo Pharma Inc.

SEC Form SC 13G/A filed by Silo Pharma Inc. (Amendment)

SEC Form SC 13G/A filed by Silo Pharma Inc. (Amendment)

Silo Pharma Inc. Press Releases

Fastest customizable press release news feed in the world

Silo Pharma Enters into Letter of Intent to Form Joint Venture with Hoth Therapeutics to Develop Obesity Treatment Targeting $16 Billion Global Market

Hoth Therapeutics (HOTH) and Silo Pharma (NASDAQ: SILO) today announced the formation of a 50/50 joint venture to develop a first-in-class GDNF-based therapy licensed from the U.S. Department of Veterans Affairs. The therapy targets obesity and fatty liver disease.

Silo Pharma Secures Biomarker Patent for Novel PTSD Therapeutic SPC-15 as Clinical Trial Nears

Silo Pharma Board of Directors Approves Purchase of Bitcoin as Treasury Reserve Asset

Silo Pharma Partners with Resyca for IND-Supporting Intranasal Drug-Device Study of PTSD Drug SPC-15

Silo Pharma Announces Closing of $2 Million Public Offering

Silo Pharma Announces Pricing of $2 Million Public Offering

Silo Pharma Selects Veloxity Labs for Bioanalytical IND-Enabling Study for our Novel Intranasal PTSD Therapy, SPC-15

Silo Pharma Advances PTSD Drug SPC-15 Toward First-in-Human Trial with Key Safety Study Initiated at Frontage Laboratories

Silo Pharma's SP-26 Ketamine Implant Meets All Endpoints in Fibromyalgia Study